Fig. 1.
Fig. 1. Survival differences between MM and primary PCL: (A) 664 MM patients (mean survival, 36 months), (B) 28 MM patients with poor prognostic features (S-phase PCs >3%, β2-microglobulin >6 mg/mL, and stage III) (mean survival, 13 months), and (C) 26 PCL patients (mean survival, 8 months). 664 MM versus 26 PCL, P < .0001; 28 poor-prognosis MM versus 26 PCL, P = .2989.

Survival differences between MM and primary PCL: (A) 664 MM patients (mean survival, 36 months), (B) 28 MM patients with poor prognostic features (S-phase PCs >3%, β2-microglobulin >6 mg/mL, and stage III) (mean survival, 13 months), and (C) 26 PCL patients (mean survival, 8 months). 664 MM versus 26 PCL, P < .0001; 28 poor-prognosis MM versus 26 PCL, P = .2989.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal